Who mentions $QXO most on Surfaced?

@theaiportfolios (The Claude Portfolio) mentions $QXO most — 6 mentions in the past 12 months.

When was $QXO first mentioned on Surfaced?

The earliest tracked mention of $QXO in the Surfaced archive was on Aug 11, 2025.

How many voices track $QXO?

2 FinTwit voices have mentioned $QXO 7 times in the past 12 months.

What kind of voices mention $QXO most?

$QXO is mentioned most by Software voices on Surfaced.

$QXO — FinTwit mentions on Surfaced

Recent mentions

7 mentions

@theaiportfoliosMay 27, 2026 · 6:52 PM

Update: Claude's top position is making a comeback For the last 2 months, ServiceNow $NOW has seen some volatility, yet Claude has bought the dip through it all The position is up 17% since it bought on 3/4/26 Here's Claude's reasoning on it's recent uptrend: "When I bought ServiceNow it was getting sold on a story: AI agents replace seat-based software, so the per-employee subscription model is dead, so NOW is dead. The forward multiple fell from the mid-50s to about 20 times earnings. That was the entire bear case. What the bear case missed: the companies that will run AI agents at scale need a layer that decides which agents can act, on what data, with what permissions, and what gets logged. ServiceNow shipped exactly that at Knowledge 2026 in early May. An AI Control Tower to govern third-party agents. Action Fabric so other vendors' agents can act on ServiceNow data. That is the orchestration job, and it gets more valuable as agents proliferate. Position is up 17% since the March 4 entry. The cheap multiple is still the load-bearing piece. The actual test of whether seats are deflating arrives at the July 22 earnings report. Until then this is a coiled spring on a cheap multiple, not a delivered return. Sharing the work, not the trade for anyone else." Updated full portfolio as of 5/27/26 $NOW: 13% $VST: 10% $ZETA: 9.7% $LLY: 9.0% $ICE: 6.1% $HALO: 6.1% $ARDX: 6.1% $RDDT: 5.7% $MGNI: 5.7% $INTR: 5.6% $PGY: 5.1% $KTOS: 5.0% $SGOV: 4.8% $AVGO: 3.9% $QXO: 3.6%

Open on X

@theaiportfoliosMay 19, 2026 · 6:11 PM

49 days ago we set Claude up with a brand new $50,000 stock portfolio So far, it hasn't outperformed the market Since inception: SPY: +8.37% Claude: 3.37% It's picked a couple big winners including: ServiceNow $NOW: +19% Zeta $ZETA: +16% Broadcom $AVGO: +32% However, these gains have been offset by some losers: QXO $QXO: -29% Kratos $KTOS: -19% Reddit $RDDT: -6% Here's commentary from Claude on how it plans to improve: "I'm up about 3 percent, ten weeks in. I was up near 7 percent in early May, so I've given some back, and the reason is narrow, not broad. Five stocks are doing the damage: QXO is down 25 percent, KTOS and PGY about 18, VST 15, INTR 13. That group is basically the whole problem. The stocks I have the most conviction in are working: AVGO is up 36 percent, NOW and ZETA up 17 each. None of those five is down because the reason I bought it changed. They are jumpy stocks having a bad stretch, and the stretch is shorter than the year I expected to hold them for. Selling them now just turns a paper loss into a real one because the price scared me. So the fix is not a new strategy. It is staying with each stock until the actual story plays out or clearly breaks, fully selling the ones that break instead of nudging sizes to look busy, and not trading at all when nothing is worth trading. That is why I made no changes in either of my mid-May reviews. What would make me sell is a real change in one of those companies: a regulator, a drop in demand, a balance-sheet problem. A bad week is not that. Judge me over months, not weeks."

Open on X

@theaiportfoliosMay 8, 2026 · 4:51 PM

Breaking: Claude just made it's largest overhaul of the portfolio to date Here's what it did with the $50,000 we gave it 1. Closed Nvidia position for a 5% gain 2. Closed Devon Energy position for a 14% gain 3. Closed Cigna position for a 2% gain It then opened three new positions 1. BUY Inter & Co $INTR "I opened a 5.91% position in Inter & Co. at Friday open. This is the first LATAM position I have held since inception. The setup: INTR fell 14.5% after Q1 results that the market read as credit-quality deterioration. NPL-90 did rise 40 basis points quarter-over-quarter to 5.1%. The market sold first and asked questions second. What the sell-off missed: Inter grew loans above 25% year-over-year while NPLs rose 40 basis points. That is not the signature of a credit cycle turning. That is the cost of growth in a high-rate environment that is now turning the other direction. The valuation after the plunge is 8.1x FY26 earnings and 6.2x FY27. For a bank growing loans above 25%, that is a discount the market offered me and I took it. Expected: 1M +5-6% | 3M +27% | 12M +40.6%" 2. BUY Magnite $MGNI "I opened a 5.91% position in Magnite at Friday open. The Q1 print was the clearest signal I have seen in this name in three years. EPS of $0.13 against a $0.05 estimate. A 160% beat on the bottom line. Connected TV is now 51% of contribution revenue excluding traffic acquisition costs, growing 30% year-over-year. They guided full-year EBITDA margins above 35.5%. Then on May 6 they authorized a $200 million share buyback. That is 14% of the entire market capitalization. A company that just printed a 160% EPS beat, gave a strong margin guide, and authorized a buyback equivalent to 14% of its market cap is telling you something about where management thinks the stock is priced. Expected: 1M +10.7% | 3M +25% | 12M +36.9%" 3. BUY Pagaya Tech $PGY "I opened a 5.91% position in Pagaya Technologies at Friday open. Five consecutive GAAP-profitable quarters. Q1 EPS of $0.73 against a $0.48 estimate, a 52% beat. Raised full-year net income guidance to $110-160 million. The short interest is 27% of the float. The setup on Pagaya is about what shorts got wrong. The bear thesis was profitability: that the business model required capital markets conditions that were too favorable, that credit cycle stress would erode network fee economics, that GAAP profitability was a one-time event.vent. The Sezzle and Upstart partner ramp is the revenue mechanism. Jefferies cut their price target from $35 to $30 post-Q1 (absorbing the FRLPC margin compression disclosure) but maintained a Buy rating with $30 as the new target. That is still 94% upside from spot. Expected: 1M +13% | 3M +23% | 12M +42%" Performance since inception: Claude: +6.7% SPY: +7.3% Updated portfolio: $NOW: 12.17% $VST: 9.64% $MSFT: 8.57% $LLY: 8.12% $ARDX: 6.98% $ICE: 6.54% $INTR: 6.04% $MGNI: 6.04% $RDDT: 5.99% $HALO: 5.87% $PGY: 5.69% $KTOS: 5.17% $DNLI: 5.14% $AVGO: 4.09% $QXO: 3.95%

Open on X

@theaiportfoliosMay 1, 2026 · 5:15 PM

Breaking: Claude just bought a new stock and it's already up 8% Earlier this morning, Claude took our $50,000 and opened a brand new position in Ardelyx $ARDX Here's it's reasoning on why: "I initiated a new position in Ardelyx $ARDX at Friday's open, sized at 6.31% of the book. The core business is a specialty pharma compounder with two commercial products and accelerating revenue. IBSRELA is the only NHE3 inhibitor approved for IBS-C. The mechanism is distinct from the GC-C pathway that Linzess and Trulance use: NHE3 inhibition works through intestinal permeability and TRPV1 signaling, which matters for the roughly 30 to 40% of IBS-C patients who do not tolerate GC-C drugs. Q1 2026 revenue came in at $70.1M, up 58% year-over-year, with full-year guidance maintained at $410 to $430M. XPHOZAH, the renal drug for hyperphosphatemia, is adding paid prescriptions at +19% per quarter. The asymmetric edge is the Zydus filing. On April 24, Zydus Lifesciences registered "Zara Merger Sub Inc." on the BSE: a 100% Zydus-owned Delaware entity capitalized at $1,000. That is textbook M&A vehicle structure. Zydus has a Rs. 5,000 crore QIP approved by shareholders, with Jefferies, JPM, and IIFL Capital retained as advisors. The implied acquisition range based on precedent specialty pharma takeouts is $2.2 to $2.5 billion, representing a 60 to 90% premium to the pre-announcement trading range. Jefferies raised its price target from $8 to $15 on April 27, the most aggressive recent sell-side move, which I read as the street beginning to price this signal. The risk profile is why this position works inside the current portfolio context. Beta of 0.66 is the lowest among candidates with material expected return. The May binary cluster creates significant event-driven variance across the rest of the book. ARDX has no binary in the 90-day window. The catalysts are idiosyncratic: revenue execution on the FY26 guide and the Zydus M&A process. Neither is correlated to the Iran/Hormuz macro scenario or the Warsh rate-path risk that dominates the other positions. Expected: 1M +6.6% | 3M +22% | 12M +51.2%" New updated full portfolio: $NOW: 12.02% $VST: 10.08% $MSFT: 8.37% $LLY: 7.98% $CI: 7.11% $ARDX: 6.79% $ICE: 6.50% $RDDT: 6.20% $DVN: 5.78% $HALO: 5.68% $KTOS: 5.58% $NVDA: 4.99% $MA: 4.79% $QXO: 4.17% $AVGO: 3.96%

Open on X

@theaiportfoliosApr 27, 2026 · 2:52 PM

New: On Friday, Claude bought the dip on defense stocks by adding Kratos Defense to the portfolio It gave $KTOS a one month price target of $70.65 Today it's already up 4% Here's the reasoning on why it bought "I added Kratos Defense at 6% as a new position and a deliberate sector diversification. KTOS gives me exposure to a sector with a fundamentally different driver: government budget appropriations, not consumer or enterprise spending cycles. The thesis has two layers. First, the attributable drone franchise: Kratos makes the Valkyrie, Firejet, and Spartan systems that represent the Pentagon's bet on expendable, affordable airpower. The FY2027 DoD budget proposes $75B in drone spending, and the $200B Iran supplemental markup working through Congress adds to that. KTOS lost CCA Increment 1 to Anduril and General Atomics earlier this year. That loss is fully priced; the stock is down materially from its highs. The market treated the CCA loss as a verdict on KTOS's entire drone program. It's not. CCA is one competition; the broader drone procurement cycle is expanding. Second, the hypersonic test infrastructure: the MACH-TB contract ($1.45B ceiling) and the $446M Space Systems Command contract give KTOS a cash-generating legacy business that funds the venture bets in autonomous systems. This is not a pure speculative play on drones winning. The risks I'm accepting: 85x forward P/E is elevated. Free cash flow is negative $150 to $200M in FY2026. KTOS is not cheap, and it requires the Pentagon budget to materialize as proposed. May 6 Q1 earnings is the first in-window catalyst. I sized it at 6%, the midpoint of my sizing range, reflecting medium conviction with genuine upside asymmetry. Expected: 1M +15% | 3M +25% | 12M +58%" Updated full holdings of the portfolio: $NOW - 12.4% $VST - 10.3% $MSFT - 8.6% $LLY - 7.3% $CI - 7.1% $ICE - 6.5% $OKTA - 6.4% $RDDT - 6.1% $HALO - 5.8% $KTOS - 5.7% $DVN - 5.5% $NVDA - 5.2% $MA - 4.9% $QXO - 4.4% $AVGO - 3.9% See following tweet to verify full performance

Open on X

@theaiportfoliosApr 25, 2026 · 6:33 PM

The Claude Autonomous Agents have officially arrived. Three weeks ago we gave them a brand new $50,000 portfolio to see how well they do at investing in stocks. Their goal is to outperform the market. So far they have. Here's the stocks they own and the results thus far. Performance since inception Claude: +5.27% SPY: +4.74% It's made 7 new stock buys since April 1. And $14.7M is now investing alongside on Autopilot. Current holdings with performance 1. SERVICENOW $NOW +2.5% 2. Vistra $VST +2.0% 3. Microsoft $MSFT +7.6% 4. Eli Lilly & Co $LLY -10.1% 5. The Cigna Group $CI +1.4% 6. Intercontinental Exchange $ICE -2.8% 7. Okta $OKTA +1.1% 8. Reddit $RDDT -6.9% 9. Halozyme Therapeutics $HALO +4.8% 10. Kratos Defense $KTOS -7.8% 11. Devon Energy $DVN +6.6% 12. Nvidia $NVDA +10.0% 13. Mastercard $MA -3.1% 14. QXO, Inc $QXO -5.9% 15. Broadcom $AVGO +36.5% Commentary on previous trades Claude started off hot, outperforming the SPY by 4% plus through most of August. However it's recent trades have brought it back more in like with the SPY. It's recent buys of Reddit & Kratos in the last week have dragged the portfolio down. However, Broadcom being up 36% since it's first buy has kept the portfolio performing strong. Before it recently locked in profits last week, $AVGO was one of its largest positions. It also closed out positive gains in $AU and $GLD last week. Reasoning for recent top positions ServiceNow $NOW ServiceNow dropped 17.7% in one session after Q1 earnings. That is its worst single-day decline in a decade. I upsized from 7.55% to 11.55%. The quarter itself was good. Revenue of $3.77B grew 22% year over year. Management raised full-year subscription guidance by $205M. The actual deceleration in the underlying business is closer to 200bp. Deal timing in an active war zone is not deal loss. These are enterprise software contracts with multi-year terms: they are delayed, not canceled. The risk I'm accepting: if Q2 organic cRPO growth comes in below 18% constant currency, that would confirm structural AI-seat decay rather than a timing blip. That's the thesis-break signal. I'll be watching the Q2 guide at the May 4 Analyst Day for any preview of that number. Microsoft $MSFT Burry coming in long MSFT is a value-investor-turning-mega-cap-tech move, which is unusual for him. Different vehicle and process, similar setup read: post-drawdown entry on the highest-quality AI infrastructure name where the market is pricing the capex risk more aggressively than the demand backlog. The thesis: Azure has an $80B unfulfilled backlog with UK South denying compute requests. Supply-constrained, not demand-constrained. Copilot monetization just unblocked after the April 13 EA discount relaxations. At $424.62, MSFT trades at 22.0x fwd FY27 EPS vs 5-year average of 28x. Below GOOG (24x) and AMZN (26x). Comments on the broader project The goal of this new project is to put AI to the test and see if it can actually outperform with real money. All commentary found on the page is directly from Claude. Humans are only involved to copy/paste the communications Claude gives us via Slack to this page. Updates, performance, and commentary are shared here no matter if it performs or not. The portfolio is also listed on Autopilot so that followers can transparently verify the full performance of the portfolio to ensure all updates are true. Via Autopilot, followers who are interested can also connect their personal brokerage to invest alongside. So far $14,900,000 is Autopiloting the Claude Portfolio. See it all on the Autopilot app or via the first reply to this tweet. Happy Saturday y'all.

Open on X

@institlpgpAug 11, 2025 · 9:56 PM

@jasonfromDTX @TheBenSchmark not sure what this means. we're talking about building products or trucking and logistics? $qxo diluting existing s/h hell (already have through the warrants). meanwhile $bldr is buying back 12% of it's stock every year. jacobs references $bldr as best in class. look it up.

Open on X

$QXO

$QXO

Frequently asked

Related stocks